<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697186</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202119</org_study_id>
    <nct_id>NCT04697186</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy</brief_title>
  <official_title>Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating efficacy and safety of berberine hydrochloride, amoxicillin and&#xD;
      rabeprazole triple therapy versus bismuth-containing quadruple therapy(amoxicillin,&#xD;
      clarithromycin, rabeprazole and bismuth) in the first eradication treatment of H. pylori. It&#xD;
      is hypothesized that berberinehydrochloride, amoxicillin and rabeprazole triple therapy is&#xD;
      non-inferior to bismuth-containing quadruple therapy. Patients diagnosed with H. pylori&#xD;
      infection will be randomly divided into one of the above treatments. At week 6 follow-up&#xD;
      visits, a urea breath test，rapid urease test or helicobacter pylori stool antigen test will&#xD;
      be performed to confirm eradication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      The study will include three phases: screening, treatment and follow-up. Screening: this&#xD;
      phase will last a maximum of 14 days and subjects eligibility will be evaluated after signing&#xD;
      informed consent. One of urea breath test，rapid urease test or helicobacter pylori stool&#xD;
      antigen test will be performed in addition to the baseline routine evaluations.&#xD;
&#xD;
      Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A&#xD;
      randomization visit will take place on Day 0 and an end-of-treatment visit will take place&#xD;
      between day 13 and 17.&#xD;
&#xD;
      Follow-up: includes one visits. Approximately 28 days after the end of treatment. Eradication&#xD;
      of H. Pylori will be confirmed by one of urea breath test，rapid urease test or helicobacter&#xD;
      pylori stool antigen test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>The primary end point of this study is H.pylori eradication,established by negative urea breath test，rapid urease test or helicobacter pylori stool antigen test 28 days after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms effective rate</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Evaluation effective rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment.&#xD;
Symptom effective rate =（total score before treatment - total score after treatment）/total score before treatment x 100%.&#xD;
Total score = frequency + severity.&#xD;
Frequency score is calculated by all the frequency of heartburn, reflux, abdominal pain, and flatulence.&#xD;
Severity is accumulated by the degree of symptoms described above, which is divided to 4 degree as 0 presenting none, and 3 presenting most severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache, dizziness, skin rash, other gastrointestinal disorders, pyrexia, cough and back pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">524</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Chronic Gastritis</condition>
  <condition>Gastric Cancer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>berberine , amoxicillin and rabeprazole triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine 300mg three time daily for 14days, amoxicillin 1000 mg and rabeprazole 10 mg by mouth, twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bismuth-containing Quadruple Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin 1000 mg，clarithromy 500mg，rabeprazole 10 mg, and Bismuth 220mg by mouth, twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.</description>
    <arm_group_label>berberine , amoxicillin and rabeprazole triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.</description>
    <arm_group_label>berberine , amoxicillin and rabeprazole triple therapy</arm_group_label>
    <other_name>Amoxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.</description>
    <arm_group_label>berberine , amoxicillin and rabeprazole triple therapy</arm_group_label>
    <other_name>Pariet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing Quadruple Therapy</arm_group_label>
    <other_name>Amoxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing Quadruple Therapy</arm_group_label>
    <other_name>Krashen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing Quadruple Therapy</arm_group_label>
    <other_name>Pariet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID</description>
    <arm_group_label>Bismuth-containing Quadruple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18~70,both gender.&#xD;
&#xD;
          2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection&#xD;
             who did not receive Helicobacter pylori eradication treatment;&#xD;
&#xD;
          3. Patients are willing to receive eradication treatment.&#xD;
&#xD;
          4. Women of childbearing age were required to use medically acceptable contraceptive&#xD;
             methods during and 30 days after the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are excluded if they have previously used antibiotics to eradicate adequately&#xD;
             recorded infection with H. pylori.&#xD;
&#xD;
          2. Patients with contraindications or allergies to the study drug.&#xD;
&#xD;
          3. Severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe&#xD;
             or unstable cardiopulmonary or endocrine diseases.&#xD;
&#xD;
          4. Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within&#xD;
             2 weeks before the [13C] urea breath test),antibiotics or bismuth complexes (more than&#xD;
             3 times /1 month before screening).&#xD;
&#xD;
          5. Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma.&#xD;
&#xD;
          6. Pregnant or lactating women.&#xD;
&#xD;
          7. Underwent upper gastrointestinal Surgery.&#xD;
&#xD;
          8. Patients with moderate to severe dysplasia or high degree of intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          9. Patients have symptom of dysphagia.&#xD;
&#xD;
         10. Evidence of bleeding or iron efficiency anemia.&#xD;
&#xD;
         11. A history of malignancy.&#xD;
&#xD;
         12. Drug or alcohol abuse history in the past 1 year.&#xD;
&#xD;
         13. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants,&#xD;
             platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).&#xD;
&#xD;
         14. Patients who has psychological problem or poor compliance.&#xD;
&#xD;
         15. Enrolled in other clinical trials in the past 3 months.&#xD;
&#xD;
         16. Refuse to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Berberine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

